Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study

Table 7 AEs in all patients with C1-INH-HAE

	Underweight BMI (n = 18)	Normal BMI (n = 210)	Overweight BMI (n = 162)	Obese BMI (n = 73)
No. of patients, no. of events	3, 3	48, 101	33, 91	19, 53
AEs related to icatibant (no. of patients, no. of events)^a	0, 0	7, 24	6, 29	2, 5
General disorders and administration site conditions	0, 0	5, 9	3, 11	1, 1
Vascular disorders	0, 0	3, 5	3, 4	1, 3
Skin and subcutaneous tissue disorders	0, 0	0, 0	2, 2	1, 1
Gastrointestinal disorders	0, 0	2, 2	1, 3	0, 0
Nervous system disorders	0, 0	1, 1	1, 2	0, 0
Investigations	0, 0	2, 5	0, 0	0, 0
Serious AEs (no. of patients, no. of events)	0, 0	20, 28	16, 32	11, 30
Serious AEs related to icatibant and (no. of patients, no. of events)^b	0, 0	0, 0	2, 3	0, 0
Skin and subcutaneous tissue disorders
Angioedema	0, 0	0, 0	1, 1	0, 0
Gastrointestinal disorders
Gastritis	0, 0	0, 0	1, 1	0, 0
Reflux esophagitis	0, 0	0, 0	1, 1	0, 0

A missing relationship to icatibant was considered related to icatibant
AE adverse event; BMI body mass index; C1-INH-HAE hereditary angioedema due to C1-inhibitor deficiency; n = number of patients
^aListed by medical dictionary for regulatory activities system organ class. Only AEs that were reported in ≥ 2 patients are presented
^bListed by medical dictionary for regulatory activities system organ class and preferred term

ISSN: 2045-7022